Utah-based Intermountain Health has launched a biotech company that it says is creating a platform of de-identified data to develop novel clinical insights, discoveries, and care processes.
Culmination Bio says its multi-modal intelligence platform provides its customers with access to omics-level data and an insights engine for medical research, health data, and healthcare services. Real-world data and evidence generation tied to the performance of diagnostics and therapeutics is a core component of the Culmination intelligence database.
Culmination launched its platform with the help of Intermountain Ventures, the strategic investment arm of Intermountain Healthcare a nonprofit health system with 33 hospitals and over 59,000 caregivers across the Western United States.
“Culmination Bio was built to expand on the success of Intermountain’s precision medicine efforts by creating longitudinal multi-modal data sets. Culmination’s powerful insights platform will unlock the next generation of discoveries to advance healthcare,” said Lincoln Nadauld, M.D., Ph.D., CEO of Culmination, in a statement. “Our focus is to discover better health for patients everywhere. Our partnership with Intermountain Health has enabled us to build a platform that will revolutionize the way we identify and implement novel clinical insights to benefit patients.”
“We are thrilled to announce our partnership with Culmination Bio and the launch of its cutting-edge clinical discovery platform,” said Nickolas Mark, of Intermountain Ventures, in a statement. “This technology will revolutionize the way clinicians and researchers identify diseases and corresponding treatments. It has been a pleasure working with the Culmination team to build out a platform that will improve patient outcomes across the board.”
The platform includes millions of data points and represents a robust environment for sophisticated queries of data to identify new diagnostic tests and treatments that will result in better care for patients, the company said.
Technology and biopharmaceutical companies, as well as healthcare institutions, will partner with Culmination in an effort to make novel medical discoveries and advances in precision medicine.
